Unmet needs in respiratory diseases: "You Can't know where you are going until you know where you have Been" - Anonymous

Clinical Reviews in Allergy and Immunology

Volumn 45, Issue 3, 2013, Pages 303-313

  Chang, Christopher ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Anti neutrophil cytoplasmic antibody; Biological modulators; Churg Strauss syndrome; Cystic fibrosis; Cystic fibrosis transmembrane conductance receptor; Gene therapy; Granulomatosus with polyangiitis; Mycobacterium tuberculosis; Pertussis; Respiratory syncytial virus; Rhinovirus; Severe acute respiratory syndrome; Tuberculosis; Vaccination; Vaccines; Wegener's granulomatosus

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; BCG VACCINE; BIOLOGICAL MARKER; CAPREOMYCIN; CHEMOKINE RECEPTOR CCR7; CYCLOSERINE; ETHIONAMIDE; GAMMA INTERFERON; HYDRALAZINE; INTERLEUKIN 18; INTERLEUKIN 33; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 5; ISONIAZID; MEDI 559; PALIVIZUMAB; PENICILLAMINE; PERTUSSIS VACCINE; PROPYLTHIOURACIL; PROTIONAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIFAMPICIN; TERIZIDONE; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ANCA ASSOCIATED VASCULITIS; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; CHRONIC DISEASE; CYSTIC FIBROSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE SEVERITY; ERADICATION THERAPY; GENE THERAPY; HEALTH CARE COST; HUMAN; INCIDENCE; LONGEVITY; LUNG TUBERCULOSIS; MORBIDITY; MORTALITY; NONHUMAN; PATIENT CARE; PERTUSSIS; PHENOTYPE; QUALITY OF LIFE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT DISEASE; SEVERE ACUTE RESPIRATORY SYNDROME; UNITED STATES; VIRAL GENE THERAPY;

ANIMALS; HUMANS; RESPIRATORY TRACT DISEASES;

EID: 84891154772     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-013-8399-2     Document Type: Article

References (149)

1. Liu W, Peng B, Lu Y, Xu W, Qian W, Zhang JY (2011) Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis. Autoimmun Rev 10:331-335
2. Kuo CH, Kuo HF, Huang CH, Yang SN, Lee MS, Hung CH (2013) Early life exposure to antibiotics and the risk of childhood allergic diseases: an update from the perspective of the hygiene hypothesis. J Microbiol Immunol Infect Wei mian yu gan ran za zhi 46:320-329
3. Velazquez JR, Teran LM (2011) Chemokines and their receptors in the allergic airway inflammatory process. Clin Rev Allergy Immunol 41:76-88
4. Walsh GM (2013) Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma. Biologics 7:7-11
5. Abonia JP, Putnam PE (2011) Mepolizumab in eosinophilic disorders. Expert Rev Clin Immunol 7:411-417
6. Wechsler ME (2013) Inhibiting interleukin-4 and interleukin-13 in difficult-to-control asthma. N Engl J Med 368:2511-2513
7. Wenzel S, Ford L, Pearlman D et al (2013) Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368:2455-2466
8. Gershwin ME, Albertson TE (2012) The practical understanding and treatment of asthma. Clin Rev Allergy Immunol 43:1-2
9. Chang C (2012) Asthma in children and adolescents: a comprehensive approach to diagnosis and management. Clin Rev Allergy Immunol 43:98-137
10. Matucci A, Vultaggio A, Ridolo E, Maggi E, Canonica GW, Rossi O (2012) Asthma: developments in targeted therapy. Expert Rev Clin Immunol 8:13-15
11. Vatti RR, Teuber SS (2012) Asthma and pregnancy. Clin Rev Allergy Immunol 43:45-56
12. Adams JY, Sutter ME, Albertson TE (2012) The patient with asthma in the emergency department. Clin Rev Allergy Immunol 43:14-29
13. Kenyon NJ, Morrissey BM, Schivo M, Albertson TE (2012) Occupational asthma. Clin Rev Allergy Immunol 43:3-13
14. Louie S, Morrissey BM, Kenyon NJ, Albertson TE, Avdalovic M (2012) The critically ill asthmatic - from ICU to discharge. Clin Rev Allergy Immunol 43:30-44
15. Leong AB, Ramsey CD, Celedon JC (2012) The challenge of asthma in minority populations. Clin Rev Allergy Immunol 43:156-183
16. Zeki AA, Kenyon NJ, Yoneda K, Louie S (2012) The adult asthmatic. Clin Rev Allergy Immunol 43:138-155
17. Belgrave DC, Custovic A, Simpson A (2013) Characterizing wheeze phenotypes to identify endotypes of childhood asthma, and the implications for future management. Expert Rev Clin Immunol 9:921-936
18. Lazic N, Roberts G, Custovic A et al (2013) Multiple atopy phenotypes and their associations with asthma: similar findings from two birth cohorts. Allergy 68:764-770
19. Curtin JA, Simpson A, Belgrave D, Semic-Jusufagic A, Custovic A, Martinez FD (2013) Methylation of IL-2 promoter at birth alters the risk of asthma exacerbations during childhood. Clin Exp Allergy 43:304-311
20. Poon AH, Hamid Q (2012) Asthma endotypes: the right direction towards personalized medicine for asthma. Expert Rev Clin Immunol 8:595-596
21. Melen E, Himes BE, Brehm JM et al (2010) Analyses of shared genetic factors between asthma and obesity in children. J Allergy Clin Immunol 126(631-637):e631-e638
22. Bhat KD, Calhoun WJ (2011) Symptom-adjusted therapy in asthma: it is time to listen to our patients. Expert Rev Clin Immunol 7:259-261
23. Rommens JM, Zengerling-Lentes S, Kerem B, Melmer G, Buchwald M, Tsui LC (1989) Physical localization of two DNA markers closely linked to the cystic fibrosis locus by pulsed-field gel electrophoresis. Am J Hum Genet 45:932-941
24. Kerem B, Rommens JM, Buchanan JA et al (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073-1080
25. Buchwald M, Tsui LC, Riordan JR (1989) The search for the cystic fibrosis gene. Am J Physiol 257:L47-L52
26. Tsui LC (1989) Tracing the mutations in cystic fibrosis by means of closely linked DNA markers. Am J Hum Genet 44:303-306
27. Tsui LC, Rommens JM, Burns J et al (1988) Progress towards cloning the cystic fibrosis gene. Philos Trans R Soc Lond B Biol Sci 319:263-273
28. Duncan AM, Buchwald M, Tsui LC (1988) In situ hybridization of two cloned chromosome 7 sequences tightly linked to the cystic fibrosis locus. Cytogenet Cell Genet 49:309-310
29. Tsui LC, Plavsic N, Markiewicz D et al (1987) Molecular approaches to the cystic fibrosis gene. Prog Clin Biol Res 254:73-87
30. Tsui LC, Buchwald M, Barker D et al (1985) Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science 230:1054-1057
31. Knowlton RG, Cohen-Haguenauer O, Van Cong N et al (1985) A polymorphic DNA marker linked to cystic fibrosis is located on chromosome 7. Nature 318:380-382
32. Tsui LC, Cox DW, McAlpine PJ, Buchwald M (1985) Cystic fibrosis: analysis of linkage of the disease locus to red cell and plasma protein markers. Cytogenet Cell Genet 39:238-239
33. Tsui LC, Zsiga M, Kennedy D, Plavsic N, Markiewicz D, Buchwald M (1985) Cystic fibrosis: progress in mapping the disease locus using polymorphic DNA markers. I. Cytogenet Cell Genet 39:299-301
34. Tsui LC, Buetow K, Buchwald M (1986) Genetic analysis of cystic fibrosis using linked DNA markers. Am J Hum Genet 39:720-728
35. Tsui LC, Zengerling S, Willard HF, Buchwald M (1986) Mapping of the cystic fibrosis locus on chromosome 7. Cold Spring Harbor Symposia on Quantitative Biology 51(Pt 1):325-335
36. Tsui LC, Rommens JM, Burns J et al (1988) Progress towards cloning the cystic fibrosis gene. Philos Trans R Soc Lond Ser B Biol Sci 319:263-273
37. Capecchi MR (2005) Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century. Nat Rev Genet 6:507-512
38. Capecchi MR (2000) How close are we to implementing gene targeting in animals other than the mouse? Proc Natl Acad Sci U S A 97:956-957
39. Capecchi MR (1994) Targeted gene replacement. Sci Am 270:52-59
40. Capecchi MR (1989) The new mouse genetics: altering the genome by gene targeting. Trends Genet TIG 5:70-76
41. Ratcliff R, Evans MJ, Cuthbert AW et al (1993) Production of a severe cystic fibrosis mutation in mice by gene targeting. Nat Genet 4:35-41
42. Ratcliff R, Evans MJ, Doran J, Wainwright BJ, Williamson R, Colledge WH (1992) Disruption of the cystic fibrosis transmembrane conductance regulator gene in embryonic stem cells by gene targeting. Transgenic Res 1:177-181
43. Smithies O, Maeda N (1995) Gene targeting approaches to complex genetic diseases: atherosclerosis and essential hypertension. Proc Natl Acad Sci U S A 92:5266-5272
44. Smithies O, Kim HS (1994) Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice. Proc Natl Acad Sci U S A 91:3612-3615
45. Koller BH, Kim HS, Latour AM et al (1991) Toward an animal model of cystic fibrosis: targeted interruption of exon 10 of the cystic fibrosis transmembrane regulator gene in embryonic stem cells. Proc Natl Acad Sci U S A 88:10730-10734
46. Smithies O, Powers PA (1986) Gene conversions and their relation to homologous chromosome pairing. Philos Trans R Soc Lond Ser B Biol Sci 312:291-302
47. Smithies O (1986) Direct alteration of a gene in the human genome. J Inherit Metab Dis 9(Suppl 1):92-97
48. Burney TJ, Davies JC (2012) Gene therapy for the treatment of cystic fibrosis. Appl Clin Genet 5:29-36
49. Ferec C, Cutting GR (2012) Assessing the disease - liability of mutations in CFTR. Cold Spring Harb Perspect Med 2:a009480
50. Rowe SM, Borowitz DS, Burns JL et al (2012) Progress in cystic fibrosis and the CF Therapeutics Development Network. Thorax 67:882-890
51. Borchers AT, Chang C, Gershwin ME, Gershwin LJ (2013) Respiratory syncytial virus - a comprehensive review. Clin Rev Allergy Immunol. doi: 10.1007/s12016-013-8368-9
52. Shaw CA, Ciarlet M, Cooper BW et al (2013) The path to an RSV vaccine. Curr Opin Virol 3:332-342
53. Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS (2013) Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 31(Suppl 2):B209-B215
54. Beeler JA, Eichelberger MC (2013) Influenza and respiratory syncytial virus (RSV) vaccines for infants: safety, immunogenicity, and efficacy. Microb Pathog 55:9-15
55. Castilow EM, Olson MR, Varga SM (2007) Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol Res 39:225-239
56. Openshaw PJ, Culley FJ, Olszewska W (2001) Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 20(Suppl 1):S27-S31
57. Schickli JH, Kaur J, Tang RS (2012) Nonclinical phenotypic and genotypic analyses of a phase 1 pediatric respiratory syncytial virus vaccine candidate MEDI-559 (rA2cp248/404/1030DeltaSH) at permissive and non-permissive temperatures. Virus Res 169:38-47
58. Meijboom MJ, Pouwels K, Luytjes W, Postma MJ, Hak E (2013) RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population. Vaccine. doi: 10.1016/j.vaccine.2013.10.023
59. Kurzweil V, Tang R, Galinski M et al (2013) Translational sciences approach to RSV vaccine development. Expert Rev Vaccines 12:1047-1060
60. Rigter A, Widjaja I, Versantvoort H et al (2013) A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PloS one 8:e71072
61. Yang CF, Wang CK, Malkin E et al (2013) Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine. Vaccine 31:2822-2827
62. Fretzayas A, Papadopoulou A, Kotzia D, Moustaki M (2012) The recent progress in RSV vaccine technology. Recent Patents Anti-Infect Drug Discov 7:237-241
63. Blanco JC, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN (2010) New insights for development of a safe and protective RSV vaccine. Hum Vaccines 6:482-492
64. Schickli JH, Dubovsky F, Tang RS (2009) Challenges in developing a pediatric RSV vaccine. Hum Vaccines 5:582-591
65. Zeng R, Zhang Z, Mei X, Gong W, Wei L (2008) Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-like protein in mice. Biochem Biophys Res Commun 377:495-499
66. Tang RS, Spaete RR, Thompson MW et al (2008) Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. Vaccine 26:6373-6382
67. Singh SR, Dennis VA, Carter CL et al (2007) Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model. Vaccine 25:6211-6223
68. Benoit A, Huang Y, Proctor J, Rowden G, Anderson R (2006) Effects of alveolar macrophage depletion on liposomal vaccine protection against respiratory syncytial virus (RSV). Clin Exp Immunol 145:147-154
69. Gonzalez IM, Karron RA, Eichelberger M et al (2000) Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine 18:1763-1772
70. Whitehead SS, Hill MG, Firestone CY et al (1999) Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates. J Virol 73:9773-9780
71. Herlocher ML, Ewasyshyn M, Sambhara S et al (1999) Immunological properties of plaque purified strains of live attenuated respiratory syncytial virus (RSV) for human vaccine. Vaccine 17:172-181
72. Crowe JE Jr (1995) Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development. Vaccine 13:415-421
73. Zaman K (2010) Tuberculosis: a global health problem. J Health Popul Nutr 28:111-113
74. Wallis RS, Pai M, Menzies D et al (2010) Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 375:1920-1937
75. Pokkali S, Das SD, Logamurthy R (2008) Expression of CXC and CC type of chemokines and its receptors in tuberculous and non-tuberculous effusions. Cytokine 41:307-314
76. Sutherland JS, Hill PC, Adetifa IM et al (2011) Identification of probable early-onset biomarkers for tuberculosis disease progression. PloS One 6:e25230
77. Mustafa T, Mogga SJ, Mfinanga SG, Morkve O, Sviland L (2006) Immunohistochemical analysis of cytokines and apoptosis in tuberculous lymphadenitis. Immunology 117:454-462
78. Akgun M, Saglam L, Kaynar H et al (2005) Serum IL-18 levels in tuberculosis: comparison with pneumonia, lung cancer and healthy controls. Respirology 10:295-299
79. Song CH, Lee JS, Nam HH et al (2002) IL-18 production in human pulmonary and pleural tuberculosis. Scand J Immunol 56:611-618
80. Subramanyam S, Hanna LE, Venkatesan P, Sankaran K, Narayanan PR, Swaminathan S (2004) HIV alters plasma and M. tuberculosis-induced cytokine production in patients with tuberculosis. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res 24:101-106
81. Sutherland JS, de Jong BC, Jeffries DJ, Adetifa IM, Ota MO (2010) Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort. PloS One 5:e12365
82. Schierloh P, Aleman M, Yokobori N et al (2005) NK cell activity in tuberculosis is associated with impaired CD11a and ICAM-1 expression: a regulatory role of monocytes in NK activation. Immunology 116:541-552
83. Fujiuchi S, Matsumoto H, Yamazaki Y et al (2003) Impaired interleukin-1beta converting enzyme (ICE) activity in patients with pulmonary tuberculosis. Int J Tuberc Lung Disease Off J Int Union Tuberc Lung Dis 7:1109-1112
84. Lee JS, Song CH, Kim CH et al (2002) Profiles of IFN-gamma and its regulatory cytokines (IL-12, IL-18 and IL-10) in peripheral blood mononuclear cells from patients with multidrug-resistant tuberculosis. Clin Exp immunol 128:516-524
85. Demangel C, Palendira U, Feng CG, Heath AW, Bean AG, Britton WJ (2001) Stimulation of dendritic cells via CD40 enhances immune responses to Mycobacterium tuberculosis infection. Infect Immun 69:2456-2461
86. Song CH, Kim HJ, Park JK et al (2000) Depressed interleukin-12 (IL-12), but not IL-18, production in response to a 30- or 32-kilodalton mycobacterial antigen in patients with active pulmonary tuberculosis. Infect Immun 68:4477-4484
87. Thaiss CA, Kaufmann SH (2010) Toward novel vaccines against tuberculosis: current hopes and obstacles. Yale J Biol Med 83:209-215
88. Clemens J, Holmgren J, Kaufmann SH, Mantovani A (2010) Ten years of the Global Alliance for Vaccines and Immunization: challenges and progress. Nat Immunol 11:1069-1072
89. Kaufmann SH, Hussey G, Lambert PH (2010) New vaccines for tuberculosis. Lancet 375:2110-2119
90. Parida SK, Kaufmann SH (2010) Novel tuberculosis vaccines on the horizon. Curr Opin Immunol 22:374-384
91. Leung CC, Lange C, Zhang Y (2013) Tuberculosis: current state of knowledge: an epilogue. Respirology 18(7):1047-1055
92. Leung CC (2013) 2012: The year in review. Part II: tuberculosis and lung disease. Int J Tuberc Lung Dis 17:1151-1159
93. Luca S, Mihaescu T (2013) History of BCG vaccine. Maedica 8:53-58
94. Zhang W, Zhang Y, Zheng H et al (2013) Genome sequencing and analysis of BCG vaccine strains. PloS One 8:e71243
95. Upadhyay P (2013) Tuberculosis vaccine trials. Lancet 381:2253-2254
96. Behr MA, Schwartzman K, Pai M (2013) Tuberculosis vaccine trials. Lancet 381:2252-2253
97. Hokey DA, Ginsberg A (2013) The current state of tuberculosis vaccines. Hum Vaccines Immunother 9(10). doi: 10.4161/hv.25427
98. Orme IM (2013) Vaccine development for tuberculosis: current progress. Drugs 73:1015-1024
99. Lalvani A, Sridhar S, Fordham von Reyn C (2013) Tuberculosis vaccines: time to reset the paradigm? Thorax 68:1092-1094
100. Bishai W, Sullivan Z, Bloom BR, Andersen P (2013) Bettering BCG: a tough task for a TB vaccine? Nat Med 19:410-411
101. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X (2010) Global tuberculosis drug development pipeline: the need and the reality. Lancet 375:2100-2109
102. Cherry JD (2013) Pertussis: challenges today and for the future. PLoS Pathog 9:e1003418
103. Leroux-Roels G (2010) Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28(Suppl 3):C25-C36
104. Rosenthal J, Rodewald L, McCauley M et al (2004) Immunization coverage levels among 19- to 35-month-old children in 4 diverse, medically underserved areas of the United States. Pediatrics 113:e296-e302
105. Hon KL (2013) Severe respiratory syndromes: travel history matters. Travel Med Infect Dis 11:285-287
106. Lelli D, Papetti A, Sabelli C, Rosti E, Moreno A, Boniotti MB (2013) Detection of coronaviruses in bats of various species in Italy. Viruses 5:2679-2689
107. Drexler JF, Corman VM, Drosten C (2013) Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS. Antiviral Res 101:45-56
108. Ge XY, Li JL, Yang XL et al. (2013) Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503:535-538
109. Cheng VC, Chan JF, To KK, Yuen KY (2013) Clinical management and infection control of SARS: lessons learned. Antiviral Res 100:407-419
110. Hui DS (2013) Severe acute respiratory syndrome (SARS): lessons learnt in Hong Kong. J Thorac Dis 5:S122-S126
111. Chan PK, Chan MC (2013) Tracing the SARS-coronavirus. J Thorac Dis 5:S118-S121
112. To KK, Hung IF, Chan JF, Yuen KY (2013) From SARS coronavirus to novel animal and human coronaviruses. J Thorac Dis 5:S103-S108
113. Hajjar SA, Memish ZA, McIntosh K (2013) Middle East respiratory syndrome coronavirus (MERS-CoV): a perpetual challenge. Ann Saudi Med 33:427-436
114. Al-Tawfiq JA (2013) Middle East respiratory syndrome-coronavirus infection: an overview. J Infect Public Health 6:319-322
115. Geng H, Tan W (2013) A novel human coronavirus: Middle East respiratory syndrome human coronavirus. Science China Life Sci 56:683-687
116. MMWR (2013) Update: Recommendations for Middle East respiratory syndrome coronavirus (MERS-CoV). Morbidity and Mortality Weekly Report 62:793-796
117. Gomersall CD, Joynt GM (2013) Middle East respiratory syndrome: new disease, old lessons. Lancet 381:2229-2230
118. Lu L, Liu Q, Du L, Jiang S (2013) Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microbes Infect Inst Pasteur 15:625-629
119. Lim PL, Lee TH, Rowe EK (2013) Middle East respiratory syndrome coronavirus (MERS CoV): update 2013. Curr Infect Dis Rep 15:295-298
120. Mailles A, Blanckaert K, Chaud P et al. (2013) First cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles=European communicable disease bulletin 18
121. MMWR (2013) Update: severe respiratory illness associated with Middle East respiratory syndrome coronavirus (MERS-CoV) - worldwide, 2012-2013. Morb Mortal Wkly Rep 62:480-483
122. Hilgenfeld R, Peiris M (2013) From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antivir Res 100:286-295
123. Lu G, Hu Y, Wang Q et al (2013) Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500:227-231
124. Kallenberg CG (2011) Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: where to go? Clin Exp Immunol 164(Suppl 1):1-3
125. Kallenberg CG (2011) Pathogenesis of ANCA-associated vasculitis, an update. Clin Rev Allergy Immunol 41:224-231
126. Cohen Tervaert JW, Damoiseaux J (2012) Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up? Clin Rev Allergy Immunol 43:211-219
127. Kallenberg CG (2012) Treatment of ANCA-associated vasculitis, where to go? Clin Rev Allergy Immunol 43:242-248
128. Cartin-Ceba R, Peikert T, Specks U (2012) Pathogenesis of ANCA-associated vasculitis. Curr Rheumatol Rep 14:481-493
129. Gomez-Puerta JA, Gedmintas L, Costenbader KH (2013) The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis. Autoimmun Rev 12:1129-1135
130. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y (2012) Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 42:145-153
131. Ben-Ami Shor D, Harel M, Eliakim R, Shoenfeld Y (2013) The hygiene theory harnessing helminths and their ova to treat autoimmunity. Clin Rev Allergy Immunol 45:211-216
132. Rook GA (2012) Hygiene hypothesis and autoimmune diseases. Clin Rev Allergy Immunol 42:5-15
133. Aujnarain A, Mack DR, Benchimol EI (2013) The role of the environment in the development of pediatric inflammatory bowel disease. Curr Gastroenterol Rep 15:326
134. Grossman C, Dovrish Z, Shoenfeld Y, Amital H (2011) Do infections facilitate the emergence of systemic sclerosis? Autoimmun Rev 10:244-247
135. Farhat SC, Silva CA, Orione MA, Campos LM, Sallum AM, Braga AL (2011) Air pollution in autoimmune rheumatic diseases: a review. Autoimmun Rev 11:14-21
136. Chighizola C, Meroni PL (2012) The role of environmental estrogens and autoimmunity. Autoimmun Rev 11:A493-A501
137. Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y (2012) Systemic lupus erythematosus one disease or many? Autoimmun Rev 11:593-595
138. Lessard CJ, Ice JA, Adrianto I et al (2012) The genomics of autoimmune disease in the era of genome-wide association studies and beyond. Autoimmun Rev 11:267-275
139. Obama B (2007) The genomics and Personalized Medicine Act of 2006. Clin Adv Hematol Oncol H&O 5:39-40
140. Costenbader KH, Gay S, Alarcon-Riquelme ME, Iaccarino L, Doria A (2012) Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev 11:604-609
141. Oertelt-Prigione S (2012) The influence of sex and gender on the immune response. Autoimmun Rev 11:A479-A485
142. Singh RP, Waldron RT, Hahn BH (2012) Genes, tolerance and systemic autoimmunity. Autoimmun Rev 11:664-669
143. Bianchi I, Lleo A, Gershwin ME, Invernizzi P (2012) The X chromosome and immune associated genes. J Autoimmun 38:J187-J192
144. Bogdanos DP, Smyk DS, Rigopoulou EI et al (2012) Twin studies in autoimmune disease: genetics, gender and environment. J Autoimmun 38:J156-J169
145. Martinez FD, Vercelli D (2013) Asthma. Lancet 382:1360-1372
146. Slager RE, Hawkins GA, Li X, Postma DS, Meyers DA, Bleecker ER (2012) Genetics of asthma susceptibility and severity. Clin Chest Med 33:431-443
147. Macneal K, Schwartz DA (2012) The genetic and environmental causes of pulmonary fibrosis. Proc Am Thorac Soc 9:120-125
148. Yang IV (2012) Epigenomics of idiopathic pulmonary fibrosis. Epigenomics 4:195-203
149. Raviglione MC, Uplekar MW (2006) WHO's new Stop TB Strategy. Lancet 367:952-955